- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Diffuse low-grade glioma misdiagnosed as acute cerebral infarction: A case report. (Pubmed Central) - Sep 20, 2022
For those cases with clinical acute neurological impairment and imaging findings similar to those of ischemic stroke, where the distribution of lesions is inconsistent with the distribution of blood vessels, and the time of onset does not match the imaging findings, the possibility of DLGGs should be considered.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Intravenous alteplase has different effects on the efficacy of aspiration and stent retriever thrombectomy: analysis of the COMPASS trial. (Pubmed Central) - Sep 20, 2022
For those cases with clinical acute neurological impairment and imaging findings similar to those of ischemic stroke, where the distribution of lesions is inconsistent with the distribution of blood vessels, and the time of onset does not match the imaging findings, the possibility of DLGGs should be considered. Prior administration of IV alteplase may adversely affect the efficacy of aspiration, but does not seem to influence the stent retriever first approach to MT in patients with anterior circulation ELVO.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Pleural effusion: Nonmalignant Pleural Effusions. (Pubmed Central) - Sep 20, 2022
A pragmatic approach to complicated parapneumonic effusions or empyemas is the insertion of a small-bore chest tube (e.g., 14-16 Fr) through which fibrinolytics (e.g., urokinase and alteplase) and DNase are administered in combination...In general, an IPC should be avoided because of the high risk of complications, particularly infections, that may jeopardize candidacy for liver transplantation. Even so, in noncandidates for liver transplant or surgical correction of diaphragmatic defects, IPC is a therapeutic option as valid as serial thoracenteses.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: SITS_ELDERLY: SITS-IVT in Patients >80 Years Study (clinicaltrials.gov) - Sep 16, 2022
P=N/A, N=933, Active, not recruiting,
TNK is noninferior to ALT at the short term efficacy outcomes: early neurological improvement and recanalization. Trial primary completion date: Aug 2022 --> Dec 2022
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Sep 16, 2022
P3, N=916, Active, not recruiting,
Trial primary completion date: Aug 2022 --> Dec 2022 Recruiting --> Active, not recruiting
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Trial completion date: SITS_ELDERLY: SITS-IVT in Patients >80 Years Study (clinicaltrials.gov) - Sep 15, 2022
P=N/A, N=933, Active, not recruiting,
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | Trial completion date: Aug 2022 --> Dec 2022
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: SITS_ELDERLY: SITS-IVT in Patients >80 Years Study (clinicaltrials.gov) - Sep 14, 2022
P=N/A, N=933, Completed,
Completed --> Active, not recruiting | Trial completion date: Aug 2022 --> Dec 2022 Active, not recruiting --> Completed
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
USE OF ALTEPLASE AND DORNASE FOR LYSIS OF COVID-19-RELATED LOCULATED PLEURAL EFFUSION (Convention Center Exhibit Hall: Rapid Area 3D) - Sep 11, 2022 - Abstract #CHEST2022CHEST_4205;
This is the first case of using alteplase and dornase for its management and we have demonstrated that it can be both a safe and effective method. Additional prospective studies are needed to further investigate this method.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
A RARE CASE OF ESCHERICHIA COLI PRESENTING IN A PRIMARY EMPYEMA (Convention Center Exhibit Hall: Rapid Area 1D) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3751;
When unusual pathogens are found in the setting of empyema it is important to evaluate possible sources of infection. In this case imaging of the abdomen, along with urine studies were performed to rule out possible primary infections.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
PERINEPHRIC MASS LEADING TO PLEURAL EMPYEMA: CONNECTING THE DOTS (Convention Center Exhibit Hall: Rapid Area 1D) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3746;
Treatment with intrapleural fibrinolytics alteplase and dornase alfa failed... Future research is needed to define the incidence, microbiology and optimal management of extra thoracic etiologies of pleural empyema.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
MANAGEMENT OF CLOT BURDEN: EKOS CATHETER-DIRECTED THROMBOLYSIS ON SEVERE DVT (Convention Center Exhibit Hall: Poster Area) - Sep 11, 2022 - Abstract #CHEST2022CHEST_3070;
The efficacy of treatment and prevention of PTS is supported by some studies with limitations. Future research is needed to assess the reduction of PTS in patients treated with CDT for clot burden in DVT.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Spinal cord infarction secondary to pulmonary embolism-induced cardiac arrest: a case report. (Pubmed Central) - Sep 10, 2022
Despite receiving high-quality cardiopulmonary resuscitation, patients with cardiac arrest are at high risk of ischemic injury to the central nervous system. After the recovery of consciousness, clinicians should pay more attention to preclude the possibility of spinal cord infarction.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion date, Trial initiation date, Trial primary completion date: Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization (clinicaltrials.gov) - Sep 8, 2022
P=N/A, N=4000, Not yet recruiting,
After the recovery of consciousness, clinicians should pay more attention to preclude the possibility of spinal cord infarction. Trial completion date: Dec 2022 --> Jun 2023 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Dec 2022 --> Jun 2023
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Clinical protocol, Journal: Control of Line Complications with KiteLock (CLiCK) in the critical care unit: study protocol for a multi-center, cluster-randomized, double-blinded, crossover trial investigating the effect of a novel locking fluid on central line complications in the critical care population. (Pubmed Central) - Sep 2, 2022
P=N/A
Success and subsequent implementation of this intervention in the ICU may also be extrapolated to other patient populations with heavy CVAD use including hemodialysis, oncology, parenteral nutrition, and pediatric patient populations. On a global scale, eradicating biofilm produced by antibiotic-resistant bacteria may serve to lessen the threat of "superbugs" and contribute to international initiatives supporting the termination of antibiotic overuse.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2429;
Tenecteplase treatment was highly cost-effective for AIS patients due to LVO compared to alteplase treatment. The finding supports tenecteplase’s broader use in acute stroke care as health outcomes improve at acceptable costs, while having practical advantages, and a similar safety profile.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion date, Trial withdrawal, Trial primary completion date: Surgical Stabilizer Assisted RVC With rtPA for CRVO (clinicaltrials.gov) - Aug 29, 2022
P1, N=0, Withdrawn,
Combination therapy was beneficial for patients with low baseline PLT to have a better reperfusion status. Trial completion date: May 2017 --> Dec 2021 | Completed --> Withdrawn | Trial primary completion date: Apr 2017 --> Dec 2021
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: A Nursing Approach to Improving Critical Care Compliance With Vital Signs and Neurological Assessments in Post-IV-Alteplase Stroke Patients. (Pubmed Central) - Aug 28, 2022
This article outlines a nursing intervention regarding the use of intravenous thrombolytic therapy for treating acute ischemic stroke, the risk factors related to IV-alteplase, best-practice protocols, and the nursing role in efforts to deliver safe care. The conclusion reveals the need for health care organizations to explore opportunities, continually inspire innovation at the bedside, highlight nursing's essential contribution to acute stroke care, and encourage publishing improvements in patient care and the nurse practice environment.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effect of Salvia Miltiorrhiza Polyphenolic Acid Injection on Improving Limb Use and Cognitive Impairment in Patients with Acute Stroke. (Pubmed Central) - Aug 28, 2022
The clinical data of 90 acute stroke patients were collected for retrospective study and divided into 45 cases each in the comparison group and the observation group according to the different treatment methods; using basic treatment + salvianolic acid, the comparison group implemented conventional alteplase and butalbital treatment, and the observation group used injectable salvianolic acid treatment, to observe and compare the clinical efficacy, changes in neurological deficits, cognitive function, and motor function scores before and after treatment in the two groups...There was no statistically significant difference in liver and kidney function and cardiac enzyme test indexes between the two groups of patients at 14 days of treatment (P > 0.05). Danshen polyphenolic acid for injection has definite clinical efficacy in the treatment of acute ischemic stroke, and it can effectively improve cognitive and motor functions and promote neurological recovery in patients with high safety.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke. (Pubmed Central) - Aug 26, 2022
There was no significant difference in all-cause inpatient mortality for alteplase versus tenecteplase (10 [5%] vs 5 [4%], P = 0.934) or in adverse events between the groups (22 [9%] vs 14 [12%], P = 0.541) for alteplase and tenecteplase, respectively. Tenecteplase had similar rates of major bleeding versus alteplase and may be a reasonable alternative in the treatment of acute ischemic stroke.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
PK/PD data, Retrospective data, Journal: Acute ischemic stroke on anti-Xa inhibitors: Pharmacokinetics and outcomes. (Pubmed Central) - Aug 25, 2022
Patients with AIS on DOAC therapy face a heightened risk of mortality. Studies are needed to investigate the safety and efficacy of thrombolysis in such patients based on time of last DOAC ingestion and/or anti-Xa/drug level.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion date, Trial primary completion date: Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis (clinicaltrials.gov) - Aug 24, 2022
P4, N=136, Recruiting,
Studies are needed to investigate the safety and efficacy of thrombolysis in such patients based on time of last DOAC ingestion and/or anti-Xa/drug level. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Jun 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: IV thrombolysis with tenecteplase for the treatment of acute ischemic stroke. (Pubmed Central) - Aug 24, 2022
IVT with tenecteplase was associated with better 3-month clinical outcomes compared to IVT with alteplase in AIS patients, with no increased risk of symptomatic intracranial bleeding. ANN NEUROL 2022;92:349-357.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion date, Trial primary completion date: FIVHeMA: Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. (clinicaltrials.gov) - Aug 24, 2022
P3, N=440, Recruiting,
ANN NEUROL 2022;92:349-357. Trial completion date: Mar 2023 --> Jan 2025 | Trial primary completion date: Oct 2022 --> Jul 2024
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: IV tenecteplase: A non-inferior alternative to alteplase? (Pubmed Central) - Aug 22, 2022
The standard medical therapy for intravenous thrombolysis in patients with stroke presenting within 3 h is alteplase, a tissue plasminogen activator. Menon and colleagues assessed the non-inferiority, efficacy, and safety of tenecteplase, a modified version of alteplase, in patients with acute ischemic stroke presenting within 4.5 h of onset.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Anaphylaxis After Alteplase During Treatment of Pulmonary Embolism (Zone 4, Science and Technology Hall, Level 200) - Aug 20, 2022 - Abstract #AHA2022AHA_6117;
Menon and colleagues assessed the non-inferiority, efficacy, and safety of tenecteplase, a modified version of alteplase, in patients with acute ischemic stroke presenting within 4.5 h of onset. Abstract is embargoed at this time.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future? (Pubmed Central) - Aug 17, 2022
Based on recent and upcoming trials, guidelines may soon recommend tenecteplase as a suitable alternative to alteplase. The use of tenecteplase in specific subgroups will depend on further recruitment to ongoing clinical trials.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Asymmetric Contralateral Angioedema After Alteplase Administration For Ischemic Stroke (Hall C) - Aug 15, 2022 - Abstract #ASA2022ASA_2381;
Asymmetric angioedema is a rare but potentially life-threatening complication of tPA administration associated with prior ACE inhibitor therapy. While cases usually respond to more conservative measures, some patients may require more urgent airway intervention in rare instances.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice. (Pubmed Central) - Aug 12, 2022
However, alteplase treatment was associated with higher risk of sICH (6.5% [685 of 10 530 patients] vs 5.3% [279 of 5249 patients]; OR, 1.28; 95% CI, 1.16-1.42; P < .001). In this observational cohort study of patients treated with EVT, intravenous alteplase treatment was associated with better in-hospital survival and functional outcomes but higher sICH risk after adjusting for other covariates.
|
